New hope for hepatitis delta: expanded access to bulevirtide
NCT ID NCT06780579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study provides access to the drug bulevirtide (Hepcludex®) for people with chronic hepatitis delta virus infection who have compensated liver disease (with or without cirrhosis). Participants must meet specific health criteria, including a positive HDV RNA test. The goal is to offer treatment to eligible patients who may benefit from this antiviral therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS DELTA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.